Tirzepatide storage and stability: what is published versus what is assumed

On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion.

Asking about tirzepatide storage and stability directly, because I have read four threads on it and each answered a slightly different question.

The version I want answered is the narrow one: given the method stated below, is the result within what anyone else has seen? I am not asking what it means yet.

Method, numbers and the two assumptions I am aware of making are below. If the assumptions are wrong that is more useful to me than agreement.

The opening post and I disagree about the size of the effect, not about the direction.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

SURMOUNT-4's randomised withdrawal design is the strongest available evidence about what happens on stopping. It says nothing about a lower maintenance dose, because the comparison was continue versus placebo rather than continue versus less.

That is the practical version. The rigorous version is longer and says the same thing.

Grateful for the specificity. Vague answers to this question are what sent me looking.

Building on post #2 rather than restating it.

Tirzepatide storage and stability: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.

Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

This is the sort of thing that ought to be settled and apparently is not.

Answering the question post #5 raises rather than the one it answers.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

This is the sort of thing the wiki should carry and currently does not.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Correct me on the arithmetic if it is wrong; I would rather know.

That matches what I have seen, for whatever a single anecdote is worth.

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

I had written a reply contradicting post #12 and deleted it. Here is what survived.

Tirzepatide storage and stability looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.

Confirming post #12 from a second method, which matters more than confirming it from a second person.

SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.

Noting that the question and the thing people usually mean by it are different.